ACCELERON PHARMA INC's ticker is XLRN and the CUSIP is 00434H108. A total of 242 filers reported holding ACCELERON PHARMA INC in Q3 2020. The put-call ratio across all filers is 0.80 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $25,033,000 | +608.9% | 145,454 | +416.9% | 0.01% | +900.0% |
| Q2 2021 | $3,531,000 | -3.8% | 28,141 | +4.0% | 0.00% | -50.0% |
| Q1 2021 | $3,670,000 | +6.8% | 27,064 | +0.8% | 0.00% | 0.0% |
| Q4 2020 | $3,435,000 | +13.1% | 26,848 | -0.5% | 0.00% | 0.0% |
| Q3 2020 | $3,037,000 | +46.9% | 26,984 | +24.3% | 0.00% | +100.0% |
| Q2 2020 | $2,068,000 | -62.5% | 21,704 | -64.6% | 0.00% | -75.0% |
| Q1 2020 | $5,509,000 | +55.3% | 61,300 | -8.4% | 0.00% | +100.0% |
| Q4 2019 | $3,547,000 | -23.2% | 66,900 | -42.8% | 0.00% | -33.3% |
| Q3 2019 | $4,619,000 | +22.4% | 116,900 | +27.2% | 0.00% | +50.0% |
| Q2 2019 | $3,775,000 | +41.2% | 91,900 | +60.1% | 0.00% | 0.0% |
| Q1 2019 | $2,673,000 | +6.6% | 57,400 | -0.3% | 0.00% | 0.0% |
| Q4 2018 | $2,507,000 | -29.2% | 57,555 | -7.0% | 0.00% | 0.0% |
| Q3 2018 | $3,543,000 | +25.9% | 61,900 | +6.7% | 0.00% | 0.0% |
| Q2 2018 | $2,814,000 | -19.5% | 58,000 | -35.1% | 0.00% | -33.3% |
| Q1 2018 | $3,496,000 | +19.4% | 89,400 | +29.6% | 0.00% | +50.0% |
| Q4 2017 | $2,928,000 | +81.9% | 69,000 | +59.9% | 0.00% | +100.0% |
| Q3 2017 | $1,610,000 | +22.8% | 43,150 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $1,311,000 | +14.8% | 43,150 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $1,142,000 | +3.7% | 43,150 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $1,101,000 | -29.5% | 43,150 | 0.0% | 0.00% | 0.0% |
| Q3 2016 | $1,562,000 | +6.5% | 43,150 | 0.0% | 0.00% | 0.0% |
| Q2 2016 | $1,466,000 | +115.6% | 43,150 | +67.6% | 0.00% | 0.0% |
| Q1 2016 | $680,000 | -42.5% | 25,750 | +6.2% | 0.00% | 0.0% |
| Q4 2015 | $1,182,000 | +72.6% | 24,250 | -11.9% | 0.00% | 0.0% |
| Q3 2015 | $685,000 | -79.6% | 27,520 | -74.1% | 0.00% | -66.7% |
| Q2 2015 | $3,361,000 | +45.1% | 106,240 | +74.5% | 0.00% | +50.0% |
| Q1 2015 | $2,317,000 | -2.3% | 60,890 | 0.0% | 0.00% | 0.0% |
| Q4 2014 | $2,372,000 | +43.2% | 60,890 | +11.1% | 0.00% | +100.0% |
| Q3 2014 | $1,657,000 | +91.3% | 54,797 | +114.9% | 0.00% | 0.0% |
| Q2 2014 | $866,000 | +1474.5% | 25,500 | +1493.8% | 0.00% | – |
| Q1 2014 | $55,000 | -56.7% | 1,600 | -50.0% | 0.00% | – |
| Q4 2013 | $127,000 | – | 3,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Darwin Global Management, Ltd. | 938,490 | $120,070,000 | 33.50% |
| Foresite Capital Management III, LLC | 108,630 | $13,898,000 | 16.15% |
| Octagon Capital Advisors LP | 112,363 | $14,376,000 | 4.98% |
| Artal Group S.A. | 1,400,000 | $179,116,000 | 3.84% |
| Avoro Capital Advisors LLC | 1,550,000 | $198,307,000 | 3.42% |
| Affinity Asset Advisors, LLC | 45,000 | $5,757,000 | 3.05% |
| NWI MANAGEMENT LP | 200,000 | $25,588,000 | 2.54% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 71,000 | $9,063,000 | 2.48% |
| FARALLON CAPITAL MANAGEMENT LLC | 2,600,000 | $332,644,000 | 2.00% |
| Parkman Healthcare Partners LLC | 52,458 | $6,711,000 | 1.72% |